Document Detail

Extracorporeal shock wave therapy ameliorates secondary lymphedema by promoting lymphangiogenesis.
MedLine Citation:
PMID:  20670777     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: Although secondary lymphedema is a common complication after surgical and radiation therapy for cancer, the treatment options for lymphedema remain limited and largely ineffective. We thus studied the effect of extracorporeal shock wave therapy on promoting lymphangiogenesis and improving secondary lymphedema.
METHODS: A rabbit ear model of lymphedema was created by disruption of lymphatic vessels. Two weeks after surgery, the lymphedematous ear was treated with or without low-energy shock waves (0.09 mJ/mm(2), 200 shots), three times per week for 4 weeks.
RESULTS: Western blot analysis showed that the expression of vascular endothelial growth factor (VEGF)-C (1.23-fold, P < .05) and VEGF receptor 3 (VEGFR3; 1.53-fold, P < .05) was significantly increased in the ears treated with shock wave than in the untreated lymphedematous ears. Compared with the control group, shock wave treatment led to a significant decrease in the thickness of lymphedematous ears (3.80 +/- 0.25 mm vs 4.54 +/- 0.18 mm, P < .05). Immunohistochemistry for VEGFR3 showed the density of lymphatic vessels was significantly increased by shock wave treatment (P < .05).
CONCLUSION: Extracorporeal shock wave therapy promotes lymphangiogenesis and ameliorates secondary lymphedema, suggesting that extracorporeal shock wave therapy may be a novel, feasible, effective, and noninvasive treatment for lymphedema.
Masayuki Kubo; Tao-Sheng Li; Takahiro Kamota; Mako Ohshima; Bungo Shirasawa; Kimikazu Hamano
Related Documents :
18952267 - Shock wave lithotripsy not associated with development of diabetes mellitus at 6 years ...
1736867 - Through curettage in the treatment of chronic canaliculitis.
3732287 - Intraaortic balloon assistance in intractable cardiogenic shock.
15971087 - Effectiveness of electro-acupuncture compared to sedo-analgesics in relieving pain duri...
19772567 - Donor site morbidity in oral mucosa graft urethroplasty: implications of tobacco consum...
8232357 - Use of botulinum toxin type f injections to treat torticollis in patients with immunity...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of vascular surgery     Volume:  52     ISSN:  1097-6809     ISO Abbreviation:  J. Vasc. Surg.     Publication Date:  2010 Aug 
Date Detail:
Created Date:  2010-07-30     Completed Date:  2010-08-31     Revised Date:  2012-10-03    
Medline Journal Info:
Nlm Unique ID:  8407742     Medline TA:  J Vasc Surg     Country:  United States    
Other Details:
Languages:  eng     Pagination:  429-34     Citation Subset:  IM    
Copyright Information:
Copyright (c) 2010 Society for Vascular Surgery. Published by Mosby, Inc. All rights reserved.
Department of Surgery and Clinical Science, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Disease Models, Animal
Lymphatic Vessels / metabolism,  physiopathology*
Lymphedema / etiology,  metabolism,  physiopathology,  therapy*
Time Factors
Vascular Endothelial Growth Factor C / metabolism
Vascular Endothelial Growth Factor Receptor-3 / metabolism
Reg. No./Substance:
0/Vascular Endothelial Growth Factor C; EC Endothelial Growth Factor Receptor-3

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Evaluating parsimonious risk-adjustment models for comparing hospital outcomes with vascular surgery...
Next Document:  Listeria monocytogenes as a rare cause of mycotic aortic aneurysm.